Khiron Life Sciences (TSXV:KHRN.H) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

KHRN.H Overzicht aandelen

Operates as an integrated medical and cannabis company in Latin America and Europe.

KHRN.H fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

De laatste financiële rapporten zijn meer dan een jaar oud

Heeft geen betekenisvolle marktkapitalisatie ( CA$9M )

Aandelen zijn zeer illiquide

Khiron Life Sciences Corp. Concurrenten

Australis Capital

CNSX:AUSA

CA$8.7m

Quantum BioPharma

CNSX:QNTM

CA$9.9m

Numinus Wellness

TSX:NUMI

CA$9.7m

CanadaBis Capital

TSXV:CANB

CA$7.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Khiron Life Sciences
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.04
52 Week Hoogtepunt	CA$0.045
52 Week Laag	CA$0.04
Bèta	0
11 maand verandering	n/a
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-87.10%
5 jaar verandering	-98.06%
Verandering sinds IPO	-96.61%

Recent nieuws en updates

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 17

Recent updates

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Apr 17

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Jun 24

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

May 03

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 06

Rendement voor aandeelhouders

	KHRN.H	CA Pharmaceuticals	CA Markt
7D	0%	0.7%	0.6%
1Y	n/a	-1.7%	23.3%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe KHRN.H presteerde ten opzichte van de Canadian Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe KHRN.H presteerde ten opzichte van de Canadian markt.

Prijsvolatiliteit

Is KHRN.H's price volatile compared to industry and market?
KHRN.H volatility
KHRN.H Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.2%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.2%
10% least volatile stocks in CA Market	3.1%

Stabiele aandelenkoers: KHRN.H heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van KHRN.H in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	n/a	Alvaro Torres	khiron.ca

Khiron Life Sciences Corp. Samenvatting

Hoe verhouden de winst en inkomsten van Khiron Life Sciences zich tot de beurswaarde?
KHRN.H fundamentele statistieken
Marktkapitalisatie	CA$9.30m
Inkomsten(TTM)	-CA$30.66m
Inkomsten(TTM)	CA$16.14m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is KHRN.H overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
KHRN.H resultatenrekening (TTM)
Inkomsten	CA$16.14m
Kosten van inkomsten	CA$9.47m
Brutowinst	CA$6.67m
Overige uitgaven	CA$37.33m
Inkomsten	-CA$30.66m

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0.0%

Hoe presteerde KHRN.H op de lange termijn?

Bekijk historische prestaties en vergelijking

KHRN.H Overzicht aandelen

Beloningen

Risicoanalyse

Khiron Life Sciences Corp. Concurrenten

CNSX:AUSA

CA$8.7m

CNSX:QNTM

CA$9.9m

TSX:NUMI

CA$9.7m

TSXV:CANB

CA$7.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Insufficient new directors

Insufficient new directors

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Khiron Life Sciences Corp. Announces Full Reimbursement by the NHS of Costs Associated to Cannabis-Based Medication and Clinic Fees for A Patient Enrolled in Zerenia Clinics UK

Third quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.019 loss in 3Q 2021)

Khiron Life Sciences Corp. to Report Q3, 2022 Results on Nov 30, 2022

Recent updates

Insufficient new directors

Insufficient new directors

Khiron Life Sciences Corp. (CVE:KHRN) Stock's 47% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Khiron Life Sciences Corp. Announces Full Reimbursement by the NHS of Costs Associated to Cannabis-Based Medication and Clinic Fees for A Patient Enrolled in Zerenia Clinics UK

Third quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.019 loss in 3Q 2021)

Khiron Life Sciences Corp. to Report Q3, 2022 Results on Nov 30, 2022

Price target decreased to CA$0.30

Khiron Launches New Cannabis Products in Europe Including Stellar Genetics from California

Second quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.032 loss in 2Q 2021)

Khiron Life Sciences Corp. to Report Q2, 2022 Results on Aug 29, 2022

Khiron Life Sciences Corp. Announces CFO Changes

Khiron Life Sciences Corp. Announces Resignation of Deborah Rosati from the Board of Directors

Chairman of the Board recently bought CA$150k worth of stock

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 4.01 million.

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.036 loss in 1Q 2021)

Khiron Life Sciences Corp. (TSXV:KHRN) entered into an agreement to acquire Pharmadrug Production GmbH from Pharmadrug Inc. (CNSX:PHRX) for $1.82 Million.

Khiron Life Sciences Corp. to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings released: EPS: CA$0.20 (vs CA$0.20 loss in FY 2020)

Price target decreased to CA$0.87

Khiron Life Sciences Corp., Annual General Meeting, Jun 23, 2022

Khiron Life Sciences Corp. Publishes Clinical Study on the Effectiveness of its Products at Controlling Chronic Pain

No longer forecast to breakeven

Khiron Life Sciences Corp. (TSXV:KHRN) acquired Mcs Clinics Limited for 0.3 million.

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Khiron Life Sciences Corp. Presents Its First Research Study with 1,400 Patients

Second quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.049 loss in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now

Insider recently sold CA$78k worth of stock

First quarter 2021 earnings released: CA$0.036 loss per share (vs CA$0.079 loss in 1Q 2020)

We're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate

Full year 2020 earnings released: CA$0.20 loss per share (vs CA$0.36 loss in FY 2019)

New 90-day high: CA$0.74

New 90-day high: CA$0.59

What Type Of Returns Would Khiron Life Sciences'(CVE:KHRN) Shareholders Have Earned If They Purchased Their SharesYear Ago?

New 90-day low: CA$0.36

Khiron Life Sciences Corp.'s Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Earnings beat expectations, revenue disappoints

Khiron Life Sciences Corp. Appoints Juan Carlos Echeverry to its Board of Directors

Third quarter 2020 earnings released: CA$0.057 loss per share

Khiron Life Sciences Corp. to Report Q3, 2020 Results on Dec 01, 2020

Khiron Life Sciences Corp. has completed a Composite Units Offering in the amount of CAD 12.6 million.

Earnings beat expectations, revenue disappoints

Second quarter 2020 earnings released: CA$0.049 loss per share

New 90-day low: CA$0.40

Khiron Life Sciences Corp. Announces Changes in Chief Financial Officer

New 90-day low: CA$0.45

Price target raised to CA$1.60

Earnings released

New 90-day low - CA$0.47

Khiron Life Sciences Corp. to Report Q2, 2020 Results on Aug 24, 2020

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Khiron Life Sciences Corp. Samenvatting

0.0x

0.0x

Inkomsten en omzet